Related articles:

ImaRx to shift focus to sale of approved drug

Administrative & Professional
Tucson Symphony
House Manager Education
Flowing Wells Schools
Spanish Teacher/High School Mechanical
Pioneer Landscaping
Diesel Fleet Mechanic Finance and Accounting
SENIOR CONTROLLER Driver/Transportation
CPC Southwest Materials
Drivers Trades/Construction
Webb Equipment Company
Laborers Administrative & Professional
Pinal County
Director I - Network Development

Tucson-based ImaRx Therapeutics Inc. has signed a letter of intent with a Canadian company to manufacture and further develop a clot-dissolving drug owned by ImaRx.

Under the pact, Microbix Biosystems Inc. of Toronto will make urokinase, a thrombolytic or clot-busting drug, which ImaRx acquired from Abbott Laboratories in 2006.

The drug, branded Abbokinase, is federally approved for treatment of patients with acute massive pulmonary embolism, or blood clots in the lungs.

ImaRx said it will retain existing supplies of the drug and exclusive rights to sell it for its currently approved use, while gaining access to a long-term supply of the drug through an agreement with Microbix.

Microbix will have the right to develop the drug for additional approved uses in vascular disease, ImaRx said.